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Abstract
Mutations in SOD1 cause hereditary variants of the fatal motor neuron disease amyotrophic lateral sclerosis (ALS).
Pathophysiology of the disease is non-cell-autonomous, with toxicity deriving also from glia. In particular, microglia
contribute to disease progression. Methylene blue (MB) inhibits the effect of nitric oxide, which mediates microglial
responses to injury. In vivo 2P-LSM imaging was performed in ALS-linked transgenic SOD1G93A mice to investigate the effect
of MB on microglia-mediated inflammation in the spinal cord. Local superfusion of the lateral spinal cord with MB inhibited
the microglial reaction directed at a laser-induced axon transection in control and SOD1G93A mice. In vitro, MB at high
concentrations inhibited cytokine and chemokine release from microglia of control and advanced clinical SOD1G93A mice.
Systemic MB-treatment of SOD1G93A mice at early preclinical stages significantly delayed disease onset and motor
dysfunction. However, an increase of MB dose had no additional effect on disease progression; this was unexpected in view
of the local anti-inflammatory effects. Furthermore, in vivo imaging of systemically MB-treated mice also showed no
alterations of microglia activity in response to local lesions. Thus although systemic MB treatment had no effect on
microgliosis, instead, its use revealed an important influence on motor neuron survival as indicated by an increased number
of lumbar anterior horn neurons present at the time of disease onset. Thus, potentially beneficial effects of locally applied
MB on inflammatory events contributing to disease progression could not be reproduced in SOD1G93A mice via systemic
administration, whereas systemic MB application delayed disease onset via neuroprotection.
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Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurolog-
ical disorder characterized by progressive loss of upper and lower
motor neurons. Transgenic mice and rats expressing various
human ALS-linked mutations in the gene encoding the enzyme
superoxide dismutase-1 (mSOD1) recapitulate to some extent the
fatal paralysis seen in patients [1,2,3,4,5,6]. Dominant mutations
in SOD1 are a frequent cause of familial ALS (fALS). Additionally,
the best-studied animal model of fALS is that caused by mutations
in SOD1 [7]. In this context, recent clinical and electrophysio-
logical data show that the human SOD1-G93A phenotype closely
resembles sporadic ALS (sALS) implicating comparable disease
pathology [8]. The mSOD1-mediated toxicity is non-cell-auton-
omous deriving not only from motor neurons but also from
neighboring glia. In particular, microglia and astrocytes substan-
tially contribute to motor neuron death and disease progression
[1,9,10,11,12]. In the case of microglia, selective silencing of the
mutant gene in these immune cells or replacement of mSOD1-
expressing cells of the myeloid lineage including microglia by non-
mutated cells via bone marrow transplantation substantially
slowed progression of the disease [1,5,9]. Such studies strongly
emphasize a microglial contribution to the progression of motor
neuron death and disease progression. Despite this clear evidence
for a neuroinflammatory role in neurodegeneration, anti-inflam-
matory therapies in mice and rats as well as in human trials have
been disappointing.
Local tissue damage within the CNS immediately attracts
microglial processes and the subsequent migration of ameboid
transformed microglia and phagocytosis [13,14,15,16,17]. Nitric
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oxide (NO), beside other signal molecules, plays a crucial role as a
chemoattractant and activator of microglia [16,18]. Spinal
superfusion with inhibitors of NO synthase (NOS) and soluble
guanylate cyclase (sGC), the main target enzyme of NO, e. g., with
the dye methylene blue (MB), efficiently inhibits injury-directed
reactions of microglia at least in the superficial layers of the dorsal
column as a sensory division of the spinal cord [16]. In addition,
microglia in SOD1G93A mice show substantial differences in
inflammatory activity within the affected lateral column of spinal
cord when compared to control mice [19], namely highly reactive
microglia in pre-clinical stages and ameboid transformed and
activated microglia with reduced injury-directed response in
clinical stages.
MB, a phenothiazine compound, has been used to treat
malaria, is the first line treatment of methemoglobinemia and is
frequently used in the treatment of ifosfamide-induced encepha-
lopathy [20]. Recently, beneficial effects in Alzheimer’s disease
(AD) have been reported [20,21,22]. Here, we used transgenic
mouse combined with time-lapse 2-photon laser-scanning micros-
copy (2P-LSM) to investigate the effect of MB on microglial
behavior in the SOD1-G93A (SOD1G93A) mouse model for ALS.
MB-treated animals were subjected to in vivo imaging to study MB
effects on microglial behavior at a cellular level in an intact
environment within lateral tracts of the spinal cord, which largely
convey efferent signals, i. e. for motor functions. To confirm local
anti-inflammatory effects, we analyzed the influence of MB on
cytokine and chemokine release from microglia of control and
advanced clinical SOD1G93A mice in vitro. Furthermore, we
investigated the effect of MB on disease onset, progression and
survival as well as on the motor behavior in the ALS model.
Additionally, we performed immunohistochemical studies with
regard to microglia and motor neurons.
Materials and Methods
Ethics statement
The experiments were performed according to the ethical
guidelines of the national animal protection law and were
authorized by the ethical committee of the State of Lower Saxony
(review board institution: Niedersa¨chsisches Landesamt fu¨r Ver-
braucherschutz und Lebensmittelsicherheit, Dezernat 33, Old-
enburg, Germany; approval-ID: 509.42502/01-39.03). Further-
more, the ARRIVE Guidelines (Animal Research: Reporting In
Vivo Experiments; NC3Rs) have been followed.
Mouse strains and motor tests
Mice transgenic for the mutated human SOD1G93A
(TgN[SOD1-G93A]G1H) were originally obtained from the
Jackson Laboratory, USA (strain: B6.Cg-Tg(SOD1-G93A)1Gur/
J) and bred at the Max Planck Institute (MPI) for Experimental
Medicine Go¨ttingen. Transgenic mice were maintained in the
hemizygous state by mating G93A males with B6SJL hybrid
females for more than 10 generations. Animals were fed standard
AIN93G diets. Drug administration was orally in drinking water
or by intraperitoneal (i. p.) injection, started at the age of 8 (oral) or
7 (i. p.) weeks. Neuropathology is first detected at this time in
SOD1G93A mice but without clinical expression of disease [23,24].
The oral study used 10 mice per group that were treated with MB
(Sigma-Aldrich, Munich, Germany) 3, 10, 30 and 100 mg per kg
body weight per day. The control group consisted of 16 mice on a
standard diet. The distribution of sexes was similar in each group.
Water consumption was monitored in 1–2 mice from each group
throughout the oral experiment in the different clinical stages. The
i. p. study used 16 mice per group and received either a daily
injection of 0.9% NaCl solution alone as control or 10 mg MB per
kg per day dissolved in 0.9% NaCl. The distribution between the
sexes was also similar in both groups.
For 2P-LSM experiments, hemizygote male TgN(SOD1-G93A)
mice (B6SJL background for more than 10 generations) were
crossbred with female TgH(CX3CR1-EGFP)xTgN(THY1-EYFP)
mice to obtain SOD1G93A mice with fluorescently labeled
microglia and projection neurons (Fig. 1F), [19,25]. Double-
transgenic TgH(CX3CR1-EGFP)xTgN(THY1-EYFP) mice were
previously obtained by crossbreeding homozygous CX3CR1-
EGFP mice, in which the expression of EGFP in microglia is
achieved by inserting the EGFP reporter gene into the Cx3cr1
locus encoding the chemokine receptor CX3CR1 [26], with
transgenic THY1-EYFP mice expressing the yellow fluorescent
protein EYFP in projection neurons and their respective axons
(Fig. 1F), [27]. TgH(CX3CR1-EGFP) mice and TgN(THY1-
EYFP) mice were of B6SJL background for more than 10
generations. The corresponding littermates (hemizygotes with
respect to all three genetic alterations) were used to study
microglial behavior in vivo. Even though female SOD1G93A
expressing mice survive few days longer than male mutant mice,
gender-dependent differences with regard to the effect of MB on
mSOD1 disease progression, and especially on microglial behavior
were not observed. Accordingly, no gender differences in the
progressive loss of functional motor units is observed in the
SOD1G93A mice [28]. The in vivo experiments were carried out on
adult mutant mice and non-transgenic littermates (referring to the
SOD1 gene; control). In control mice no age-related changes in
microglial behavior were observed within the studied ages (adult
animals). In treated mice, which were used for in vivo imaging and
immunohistochemical investigations, drug administration started
at the age of 7 weeks.
SOD1G93A mice monitored in this study showed first signs of
disease at about 100 days of age and reached end stage disease at
about 130 days of age. The mice were classified as ‘pre-clinical’
when showing no signs of motor deficits; early clinical stage (‘‘stage
1’’, onset of disease) when an abnormal gait with limb tremor was
first apparent corresponding to an age of about 105 days; clinical
stage (‘‘stage 2’’, about 115 days) when paralysis of at least one
limb was observed; and advanced clinical stage (‘‘stage 3’’, about
123 days) when righting reflex failure occurred owing to the
complete paralysis of hind limbs and at least one forelimb [29].
Animals were sacrificed when they were no longer able to right
themselves within 10 s of being placed on their sides.
Motor performance was evaluated by means of a rotarod task.
Mice were placed on a horizontal rod that was made to rotate
either constantly at 12 rounds per minute (rpm) or at 1 rpm with
an acceleration rate of 1 rpm every 10 s until the mouse fell off.
Each mouse was tested three times per trial. Rotarod tests were
started at the age of 60 days with subsequent tests at 7-day
intervals. Grip strength of the forelimbs was also measured by a
grip-strength-meter (TSE Systems, Bad Homburg, Germany)
[30,31,32]. Mice held the grip and were pulled steadily backwards
by the tail, the grip braking force being measured and expressed as
milli-newtons per gram body weight. Each mouse was tested three
times per trial.
Immunohistochemistry
The animals were anesthetized (80 mg pentobarbital sodium
per kg body weight i. p.) and perfused transcardially with PBS
followed by 4% paraformaldehyde. After tissue processing, 20 mm-
thick cryosections were cut from the lumbar spinal cord (level L3
to L5). After thawing and rehydration, the sections were incubated
with blocking buffer (5% normal goat serum and 0.1% Triton X-
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100). The following primary antibodies were used: NeuN (rabbit,
1:100; Millipore, Temecula, USA) and SMI-32 (mouse, 1:1000;
Sternbergs monoclonal, Emeryville, California, USA) to label
neurons, Iba1 to label microglia (rabbit, 1:500; Wako pure
chemical Industries, Osaka, Japan), phospho-TDP-43 (pS403/
404; rabbit, 1:500; Cosmo Bio Co LTD, Tokyo, Japan) and SOD1
(rabbit, 1:400; Enzo, Lo¨rrach, Germany). Secondary goat anti-
rabbit antibody labeled with Cy3 (1:500; Millipore, Temecula,
California, USA) was used for NeuN and Iba1. SOD1-immuno-
reactivity was developed with new fuchsin (Serva, Heidelberg,
Germany) after 1 h incubation with AP (goat anti-rabbit, 1: 50;
Dako, Hamburg, Germany) according to the manufacturer’s
instructions. For double labeling experiments, anti-SMI32 and
anti-phospho-TDP-43 were used. Immunoreactivities were de-
tected by appropriate Alexa 488 (Invitrogen, Camarillo, Califor-
nia, USA) and Cy3-conjugated secondary antibodies. Images were
obtained using a Zeiss Axioplan 2 imaging fluorescence micro-
scope (Zeiss, Jena, Germany) or a confocal laser-scanning
microscope (Leica TSC SP2; Leica Microsystems Heidelberg
GmbH) equipped with an acousto-optical beam-splitter and a 40x
(NA 1.25) oil immersion objective. For detection of Alexa 488, a
488-nm Argon laser was used and emission was recorded between
505 and 521 nm. For detection of Cy3, excitation was performed
by a 543-nm HeNe laser and emission was recorded between 553
and 630 nm. For quantification purposes of intracellular aggre-
gates, analyze particle function of ImageJ (http://rsbweb.nih.gov/
ij) was used.
To analyze motor neuron number, lumbar cross-sections of
preclinical (90-day-old), clinical (110-day-old) and advanced
clinical (about 130-day-old) mice were stained with NeuN and
analyzed. Cell somata of NeuN-positive cells in the anterior horn
which had a diameter larger than 20 mm were counted as these are
probably motor neurons. In three lumbar sections approximately
100 mm apart both anterior horns were analyzed at 10x
magnification for each mouse. The anterior horn was defined as
the grey matter anterior to the middle of the central canal [33].
After counting the number of neurons within a grid of
0.4 mm60.4 mm, these were expressed in terms of 1 mm2. These
measurements probably included interneurons of relatively large
size [34]. Tissue shrinkage and a possible loss of NeuN
immunoreactivity during the disease course, as in the case of
ischemia [35] or axotomy of the facial nerve [36], could have
further distorted a true estimate number of motor neurons,
especially in the advanced clinical stages. However, in the absence
of specific motor neuron markers, we have accepted such
inaccuracy in the comparison of cell numbers in the control and
treated mice.
Cytokine release assays
For the cytokine release studies on homogeneous cultures,
control and SOD1G93A microglia were plated in 96-well plates at a
density of 1.56104 cells per well. As a control, microglia of
newborn mice (ctrlp0) were used as previously described [37,38].
Mutant microglia were obtained from whole spinal cord dissection
of SOD1G93A mice in advanced clinical stage (stage 3). For age-
matched control, control microglia (ctrlp120) were obtained from
corresponding adult siblings. After 1 day, cells were exposed either
to fresh medium (basal release values) or medium containing LPS
(lipopolysaccharide, final concentration 1 ng/ml) (E. coli R515
(TLR4) Axxora/Appotech TLR ligand set 1 (APO-54N-018)) or
MB (1, 10, 20, 40 or 100 mM), or both. Cells were incubated for
18 h and supernatants analyzed. Cells were rinsed and new
medium was added containing WST-1 agent for a viability assay
(Roche Diagnostics). Measurements of cytokines and chemokines
in culture supernatants were performed with either factor- and
species-specific complete ELISA systems, or sets of capture and
detecting antibody pairs, in addition to standard proteins (R&D
Systems, Biolegend) as previously described in detail [37,38].
Adaptations were made to reduce sample size and assay volume.
Analyzed factors were TNFa, IL-6, IL-12p40, MCP-1, CXCL1
(KC, the mouse equivalent of GROa), CCL3 (MIP-1a) and CCL5
(RANTES).
Anesthesia and surgery
In vivo experiments were carried out on respective transgenic
SOD1G93A and control mice of corresponding age under general
anesthesia initiated by 80 mg/kg pentobarbital sodium i. p.
(dissolved in 0.9% NaCl). After cannulation of the jugular vein,
anesthesia was continued with 40–60 mg per kg and h metho-
hexital sodium (Brevimytal, Hikma, London, UK). A tracheotomy
was performed and a tube inserted for artificial ventilation. Dorsal
and left lateral surface of spinal cord segments L4 and L5 were
exposed by laminectomy of the spines L1 to L3 for imaging. The
lateral column was imaged by rotating the mice by 80 degrees.
Active respiratory movements were abolished by paralysis with
pancuronium bromide (Pancuronium Organon, Essex Pharma
GmbH, Munich, Germany; 800 mg per kg supplemented i. p.
every hour) and artificial ventilation with a gas mixture of CO2
(2.5%), O2 (47.5%), and N2 (50%) at 120 strokes/min (100–
160 ml/stroke depending on the body weight). The vertebral
column was rigidly fixed with two custom-made clamps, each
having two joints for keeping the mouse in the turned position. In
all experiments, the exposed spinal cord was continuously
superfused with ACSF (artificial cerebro-spinal fluid: 125 mM
NaCl, 25 mM NaHCO3, 2.5 mM KCl, 1.25 KH2PO4, 1 mM
MgCl2, 2 mM CaCl2*H2O and 10 mM glucose). For superfusion
of the spinal cord with MB (solved in ACSF), the dura was
carefully removed without lesioning the spinal cord. Rectal body
temperature was measured and kept between 36 and 38uC by a
heated plate. Electrocardiograms were monitored throughout the
experiment. A heart rate maintained below 420 per min (also after
noxious stimuli), as well as the need for high levels of heating were
taken as signs for adequate anesthesia under paralysis and
corresponded to the other reflex tests carried out before paralysis.
Furthermore, care was taken that the dose of anesthesia during
Figure 1. Inhibition of microglial reaction towards axonal injury in the lateral column by local application of MB in vivo. Microglial
reaction towards laser-induced axonal transections within the lateral column of the spinal cord was recorded. Tissue injuries were induced by high-
power laser pulses. The experiments have been performed in double transgenic mice expressing EGFP in microglia and EYFP in projection neurons.
For better visualization, EYFP fluorescence in the images is depicted with a red colour table. Images are arranged such that rostral is to the upper side.
(A-D) Left images were taken immediately (3 min) after axonal transection (autofluorescence and arrow) in control and mutant (SOD1G93A) mice.
Respective images (right) were taken 60 min after injury. In respective experiments spinal cord was superfused with MB (1 mM). (E) Quantification of
microglial response (increase of EGFP fluorescence around the injury) to the injured site. Control and mutant mice were of corresponding age (60 to
90 days of age). n = 7 mice for control response, n = 4 for MB-modified response in control mice, n = 9 for response in SOD1G93A mice, n = 7 for MB-
modified response in SOD1G93A mice. (F) Breeding strategy to obtain SOD1G93A mice with fluorescently labeled microglia and projection neurons.
Values are presented as mean 6 SEM; ANOVA followed by Tukey test (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0043963.g001
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paralysis was equal to, or greater than, before paralysis
[16,17,19,25,39].
2-Photon laser-scanning microscopy and image
acquisition
High resolution in vivo imaging was performed using a
commercial two-photon laser-scanning microscope (2P-LSM,
Zeiss Axiocope 2 with LSM510 NLO scanhead) equipped with
a fs-pulsed, mode-locked titanium-sapphire infrared laser (Mira
900/10 W Verdi; Coherent, Glasgow, UK) or a custom-made 2P-
LSM equipped with a fs-pulsed titanium-sapphire laser (Chame-
leon Ultra II; Coherent). For 2P-recordings, a Zeiss W Plan
Apochromat 20x (NA 1.0) water immersion objective was used.
For excitation, the laser was set at 92565 nm for the simultaneous
excitation of EGFP and EYFP. Emitted light was split by a
520 nm longpass dichroic mirror (Semrock, Rochester, USA) and
collected by photo-multiplier tubes (Hamamatsu, Japan) through
two bandpass filters: a 494620.5 nm (FF01-494/41-25) and a
542625 nm (FF01-542/50–25), respectively (Semrock). The
measured fluorescence intensities were comparable between the
two microscopes. Parallel, uniformly spaced (1.5 to 2.4 mm) planes
of 125*125 to 600*600 mm2 regions were recorded, digitized and
processed to obtain z-stacks of images (256x256 to 1024x1024
pixels in size). Voxel sizes ranged from 0.24x0.24x1.5 to
1.17x1.17x2.4 mm for the xyz-axes. The total acquisition time
for a stack of 15 to 30 images was approximately 1–2 min.
Recordings of up to 100 mm stack depth were obtained. Stacks
were acquired continuously to obtain time-lapse series of
microglial action. Reproducible lesions were applied by the
titanium-sapphire laser generally focused for about two seconds
within an axon plane until fluorescence began to increase,
resulting most often in transection of a single axon.
Image processing and morphometric analysis
Image processing and morphometric analysis were performed
using the Zeiss LSM software, ImageJ (http://rsbweb.nih.gov/ij)
and Matlab (version 7, MathWorks, Ismaning, Germany).
Statistical analysis was performed using Origin 7 software
(Northampton, USA). Prior to any analysis, the time series of
image stacks were corrected for the shifts in the horizontal and
vertical directions by using an autocorrelation based custom-made
software written in Matlab (v.7). For the majority of images
background noise was removed by the median filter of ImageJ.
The recorded stacks are shown in maximum intensity projections
(MIPs). Although EGFP and EYFP signals cannot be separated
without spectral unmixing, the filter sets were chosen in a way that
permitted an unambiguous distinction of EGFP expressing
microglia from EYFP expressing neurons. The cellular differen-
tiation was facilitated by the different morphologies of axons and
microglia and the predominance of EGFP signal in one channel.
For quantification purposes we defined the microglial response as
the increases in fluorescence directly around the injured site
[14,16,19]. Whether such increases were a consequence of process
ingrowth or soma immigration were not distinguished. We used
the function R(t) = (Rx(t)2Rx(0))/Ry(0) as described earlier
[14,16,19]. To measure the microglial density around an injury
we used the analyze particle function of ImageJ. Diameters for
outer and inner area were 70 mm and 35 mm, respectively. Care
was taken to include similar injuries in the different groups,
indicated by the average size of the autofluorescence signal.
Statistical analysis
For statistical analysis Origin 7 software (Northampton, USA)
was used. Mean values are given 6 standard of the mean (SEM).
Statistical significance (p,0.05) was determined using ANOVA
followed by the Tukey test.
Results
Inhibition of microglial activation by local application of
MB in vivo
Inhibition of the NO pathway by local spinal application of
different nitric oxide synthase (NOS) or soluble guanylate cyclase
(sGC) inhibitors blocks microglial response to injuries within the
superficial layers of the dorsal column as a sensory part of the
spinal cord [16]. To test whether inhibition of the NO pathway
influences injury-directed reactions of SOD1G93A microglia within
an affected motor part of the spinal cord, the exposed lateral
column was superfused with MB, a broadband blocker of sGC and
NOS [40]. As seen in Figure 1, superfusion with MB (1 mM)
significantly suppressed the microglial response at the site of laser-
induced axon transection within the lateral column to 12.261.9%
of the control value set as 100614.2% [19], a result comparable to
the MB-induced suppression of microglial response in the dorsal
column [16]. Figure 1A-B show a reduced accumulation rate of
control microglia around the injured axon 60 min after a laser-
induced lesion when the tissue was superfused with MB. Similar
suppression was also observed in 60 to 90-day SOD1G93A mice
containing highly reactive microglia when the MB response of
these microglia fell to 17.962.1% of the control value [19] (Fig. 1).
Figure 1C-D also show a reduced rate of accumulation of modified
microglia after injury when the tissue was exposed to MB. In the
clinical stages, when microglia show reduced injury-induced
reactions compared with control mice [19], these were also
suppressed by locally applied MB (data not shown).
Inhibition of cytokine/chemokine release from microglia
by application of MB in vitro
To determine whether locally applied MB also suppresses the
release of immunoregulatory mediators, thus to confirm an anti-
inflammatory action of MB, we measured the secretion of different
cytokines and chemokines by control (newborn mice: ctrlp0; age-
matched controls (adult siblings): ctrlp120), and mutant microglia
(advanced clinical mice: G93Ap120). For this purpose, different
concentrations of MB (1, 10, 20, 40 and 100 mM), alone or in
combination with LPS, were added to microglia cultures and the
cytokine/chemokine release was measured by ELISA. We
measured the release of the following cytokines and chemokines:
TNFa, RANTES, KC, MIP-1a, IL-6, IL-12 and MCP-1. The
viability assay using WST-1 agent showed no significantly
increased cellular death (data not shown). MB application alone
induced no distinct release response, whereas stimulation by LPS
resulted in a robust increase of all tested factors in control and
mutant microglia (Fig. 2). LPS-induced release of all tested
cytokines and chemokines from G93Ap120 microglia was not
distinctly different when compared with ctrlp120 microglia. We
observed a clear decrease of TNFa, RANTES, IL-6 and IL-12
release from G93Ap120 microglia when compared with the
respective release from ctrlp0 microglia. This is probably due to
altered expression levels in cultured microglia from adult mice or
to a lower sensitivity to LPS of cultured microglia from adult mice.
In contrast, the release of KC was increased from microglia of
adult mice. The release of MIP-1a and MCP-1 was virtually
unchanged.
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Application of MB only at the highest concentration of 100 mM
significantly reduced the LPS-triggered production of all tested
cytokines and chemokines with the exception of MIP-1a from
ctrlp120 or G93Ap120 microglia, when compared with the LPS-
triggered production from the same groups of microglia (Fig. 2). In
the case of adult microglia, only the release of RANTES from
G93Ap120 microglia and of IL-12 from ctrlp120 microglia were
significantly reduced by the application of 40 mMMB. Application
Figure 2. Inhibition of microglial cytokines and chemokines production by MB. Primary cultures of control (newborn control: ctrlp0; adult
control from corresponding siblings of mutant mice: ctrlp120) or mutant (from advanced clinical SOD1
G93A mice; G93Ap120) microglia (15,000 cells/
well) were incubated with MB (1, 10, 20, 40 and 100 mM) in the presence or absence of LPS (100 ng/ml) for 18 hours. Cytokine and chemokine release
profile was determined in the supernatants. Data are presented relative to the corresponding value of LPS-triggered cytokine or chemokine release
from control microglia of newborn mice (set as 1). Data are mean6 SEM of triplicates of 3 (MCP-1), 4 (IL-6) or 5 (TNF-a, RANTES, KC, MIP-1a and IL-12)
independent experiments; ANOVA followed by Tukey test (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0043963.g002
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of 1, 10 and 20 mM MB had no significant effects on cytokine and
chemokine release. In the case of ctrlp0 microglia, the release of all
tested cytokines and chemokines was significantly reduced by the
application of 100 mM MB, the release of TNFa, IL-6 and IL-12
being already significantly reduced by the application of 40 mM
MB and that of IL-6 and IL-12 by 10 and 20 mM MB (Fig. 2).
Application of 1 mMMB had no significant effects on cytokine and
chemokine release.
Delayed onset of disease in MB-treated SOD1G93A mice
MB has been used for a long time in various areas of biology
and medicine, e. g. as first line treatment of methemoglobinemia
[20] and recently beneficial effects of MB have been reported for
clinical trials in AD [21,22]. To test whether MB has a beneficial
effect on mSOD1 disease course, they were orally treated with MB
added to the drinking water (0, 3, 10, 30 and 100 mg per kg body
weight per day). Given the knowledge about the well-studied and
safe drug which has been also administered orally in human as
well as about its high bioavailability [41], the oral route was
chosen for MB administration. Whereas treatment with 3 or
10 mg MB significantly delayed the onset of disease compared to
controls, treatment with 30 or 100 mg had no significant effect on
disease onset (ctrl: 104.861.03 days; 3 mg: 11261.64 days;
10 mg: 111.362.74 days; 30 mg: 102.561.95 days; 100 mg:
102.962.47 days) (Fig. 3A). Correspondingly, the onset of weight
loss was delayed in mice treated with 3 or 10 mg MB (Fig. 3B), but
weight loss was not itself significantly improved by MB. The
progression to the later clinical stages (see Materials and Methods)
was only delayed in the 3 mg group by oral MB-treatment (stage
2: ctrl: 115.861.71 days, 3 mg: 122.262.06 days, 10 mg:
116.663.13 days, 30 mg: 11362.91 days, 100 mg: 116.561.92
days; stage 3: ctrl: 123.761.4 days, 3 mg: 128.762.93 days,
Figure 3. Delayed onset of disease by oral application of MB.
(A) Control and MB-treated (3, 10, 30 and 100 mg oral per kg body
weight per day) SOD1G93A mice with respect to the different stages of
disease (stage 1: onset of disease/early clinical stage; stage 2: clinical
stage; stage 3: advanced clinical stage). (B and C) Weight and survival
profiles for SOD1G93A mice (control and MB-treated). In B the data are
presented relative to the highest value in each group. Values are
presented as mean6 SEM; ctrl: n = 16 mice, 3 mg: n = 12, 10 mg: n = 10,
30 mg: n = 8, 100 mg: n = 11; ANOVA followed by Tukey test (*p,0.05,
**p,0.01).
doi:10.1371/journal.pone.0043963.g003
Figure 4. Delayed onset of disease by intraperitoneal applica-
tion of MB. (A) Control and MB-treated (10 mg intraperitoneal
injection per kg body weight per day) SOD1G93A mice with respect to
the different stages of disease. (B and C) Weight and survival profiles for
SOD1G93A mice (control and MB-treated). In B the data are presented
relative to the highest value in each group. Values are presented as
mean 6 SEM; both groups: n = 16 mice; ANOVA followed by Tukey test
(*p,0.05, ***p,0.001).
doi:10.1371/journal.pone.0043963.g004
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10 mg: 122.463.85 days, 30 mg: 121.763.39 days, 100 mg:
126.362.05 days) (Fig. 3A). Accordingly, survival time was not
significantly altered by oral MB-treatment, even though the death
was slightly delayed by the treatment with 3 mg MB and to a lesser
extent with 100 mg MB (ctrl: 12961.15 days; 3 mg: 13463.37
days; 10 mg: 12964.12 days; 30 mg: 12963.69 days; 100 mg:
13262.41 days). Figure 3C shows the corresponding survival
curves.
In another set of experiments, MB was administered by
intraperitoneal injection (Fig. 4). For this purpose, an intraperi-
toneal dose of 10 mg MB per kg body weight per day in treatment
trials of mice was chosen based on previous studies [42,43].
Treatment with 10 mg MB delayed the onset of disease by nearly
9 days (ctrl: 107.960.89 days, MB: 116.461.16 days, p,0.001)
(Fig. 4A) as was the Onset of weight loss (Fig. 4B). However,
overall weight loss was not significantly changed in MB-treated
mice. The start of the later disease stages was delayed by around 7
days (stage 2: ctrl: 117.461.45 days, MB: 124.361.73 days,
p,0.05; stage 3: ctrl: 122.561.6 days, MB: 129.161.69 days,
p,0.05) (Fig. 4A). Survival time was also extended by nearly 7
days (death: ctrl: 125.761.85 days, MB: 132.261.9 days, p,0.05).
Figure 4C shows the corresponding survival curves. Correspond-
ingly, MB treatment also delayed motor dysfunction as evaluated
by rotarod performance (Fig. 5). Grip strength of the forelimbs was
improved (not statistically significant) in clinical stages by the i. p.
treatment (data not shown).
Effect of systemic application of MB on microglial
activation and motor neuron survival
To test the influence of systemically applied MB on microglial
reaction to laser-induced axon transection within the lateral
column and on motor neuron survival, we treated SOD1G93A mice
with MB (10 mg oral per kg body weight per day) and performed
2P-LSM recordings for microglia activation and immunohisto-
chemistry for quantification of lumbar anterior horn neurons. No
significant differences were observed in control versus treated mice
when microglial reactions towards single axon transections were
studied (60 to 90-day-old; control response 10069.3%, MB-
modified response 97.466.2%) (Fig. 6). Similarly, microglial
reactions were comparable in mice at different clinical stages
(data not shown). Accordingly, Iba1 immunostaining of the
lumbar anterior horn showed no differences between MB-treated
SOD1G93A mice and controls with respect to microgliosis (Fig. 7).
To determine whether MB-induced increases in motor neuron
survival could underlie the observed delay of disease onset, NeuN-
stained cross-sections of the spinal cord at level L3 to L5 were
investigated. Pre-clinically, the number of counted neurons was
significantly higher in MB-treated (10 mg oral per kg body weight
per day) mice than in control siblings (pre-clinical 90-day-old mice:
ctrl: 70.465.77 per mm2, MB: 96.968.18) (Fig. 8A and B).
However, this difference in neuron count was not present at the
clinical and advanced clinical stages indicating only an initial and
temporary effect of MB (clinical stage at 110-day-old mice: ctrl:
Figure 5. Delayed motor disturbance by MB application. Rotarod motor performance of untreated and MB-treated (10 mg intraperitoneal
injection per kg body weight per day) SOD1G93A mice. The time until mice fell off the rotarod at 12 rpm (A) and the velocity the mice reached using
an acceleration rate of 1 rpm every 10 s (B) are presented. Each animal was tested three times per trial. Values are presented as mean 6 SEM; both
groups: n = 10 mice; ANOVA followed by Tukey test (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0043963.g005
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68.265.59 per mm2, MB: 75.866.71; advanced clinical stage at
130-day-old mice: ctrl: 36.563.2, MB: 36.466.25) (Fig. 8A and
B). To analyze intracellular aggregations in affected motor
neurons, TDP-43 and SOD1 staining was performed in lumbar
cross-sections. Figure 9 shows TDP-43-containing aggregates in
SMI-32-positive neurons in the anterior horn of control and MB-
treated pre-clinical and advanced clinical mice. We observed no
reductions of intracellular TDP-43-containing aggregates in MB-
treated mice when compared with control. In pre-clinical mice,
the fraction of the intracellular area filled with aggregates was
99.462.6% of the control value set as 10068.1% (4 mice in each
group). In clinical mice, the fraction was 101.967.5% of the
corresponding control value set as 10069.1% (3 mice in each
group). Additionally, SOD1 staining revealed no clear reductions
of intracellular SOD1-containing aggregates in lumbar anterior
horn neurons (data not shown).
Discussion
Neuroinflammation is a prominent feature of murine ALS
animal models [1,5,9,10,11,12,44]. Despite strong evidence for
microglial activation and release of pro-inflammatory cytokines
driving disease progression, anti-inflammatory strategies have
been overall disappointing.
Our earlier findings using in vivo time-lapse imaging of the spinal
cord 6dorsal tracts indicated that the NOS and sGC inhibitor
Figure 6. Effect of systemic application of MB on microglial reaction towards laser-induced axonal injury. Microglial reaction towards
laser-induced axonal transections within the lateral column of the spinal cord was recorded. Images are arranged such that rostral is to the left side.
(A) Left images were taken immediately (5 min) after axonal transection (autofluorescence and arrow) in mutant (SOD1G93A) mice. Respective images
(middle and right) were taken 30 and 60 min after injury, respectively. Upper images represent in vivo recordings of an exemplary non-treated
SOD1G93A mouse. In the lower experiment, the mouse was treated with MB (10 mg oral per kg body weight per day; drug administration started at
the age of 45 days). (B) Quantification of microglial response to the injured site. No significant differences in microglial reaction towards a laser-
induced axonal injury were observed between non-treated and MB-treated SOD1G93A mice. Mutant mice were 60 to 90 days of age. Values are
presented as mean 6 SEM; no treatment: n = 9 mice, MB-treatment: n = 8.
doi:10.1371/journal.pone.0043963.g006
Figure 7. Effect of systemic application of MB on microgliosis.
Iba1 staining of the anterior horn at level L3-L5 during the disease
course of SOD1G93A. MB-treatment did not inhibit the observed
microgliosis. Arrows point to the central canal.
doi:10.1371/journal.pone.0043963.g007
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methylene blue (MB) strongly reduce microglial activation by
inhibiting NO-mediated reactions towards tissue injury [16]. The
present study confirmed this for the lateral columns of the spinal
cord in both control and mutant mice. This region contains
efferent (motor) fibers that undergo degeneration in ALS [45,46].
Furthermore, addition to this local anti-inflammatory effect in vivo,
MB at high concentration significantly inhibited the induction of
cytokines and chemokines in control and mutant microglia in vitro.
These results prompted us to study potential therapeutic effects of
MB in an ALS mouse model.
MB influenced the course of the disease in SOD1G93A mice
when administered from preclinical stages onwards via oral or
intraperitoneal routes. For both MB significantly delayed the onset
of disease by nearly 10 days when, in the case of oral application, it
was administered at 3 or 10 mg per kg body weight per day. The
Time from onset of disease to death was not changed in either
group indicating that overall disease progression was not affected.
In confirmation, a recent study in which 1 or 10 mg MB per kg
body weight per day was administered intraperitoneally beginning
at the onset of SOD1G93A and TDP-43G348C disease showed no
extension of the lifespan [47]. Thus, neuroprotection by MB seems
to be more crucial in preclinical than in clinical stages.
A further increase of MB dose in our trial had no effect on
disease course which was unexpected in view of the previously
observed local anti-inflammatory effects after application of MB at
high doses in vivo and in vitro. Administration at 30 or 100 mg per
kg body weight per day from preclinical stages onwards had no
significant effects on onset or survival, as has been recently shown
by a treatment trial in which 25 mg per kg body weight per day
was administered orally beginning at a similar preclinical stage
[48]. Apparently, the high concentrations needed inside and
locally within the central nervous tissue for anti-inflammatory
effects cannot be achieved by increasing the dose of systematically
administered MB. Moreover, increasing the dose actually led to a
loss of the beneficial neuroprotective effects of MB when
administered at 3 or 10 mg per kg body weight per day. The
reason for this neutralization is unclear. Similar loss of beneficial
effects has been shown, for instance, for imipramine in mdx mice
[49]. As known from human clinical trials, the dose of a drug has
to be optimized as an increase may abolish beneficial effects, due,
for instance, by inducing unwanted side effects.
Earlier studies indicated that microglial activation in ALS
models influences disease progression rather than delaying the
onset of disease [1,9,10]. Accordingly, in our in vivo studies using in
vivo time-lapse imaging, we observed that microglial responses
were not affected in MB-treated mice. In particular, the microglial
reaction towards local laser lesions was unaltered, compared to
non-treated SOD1G93A mice, indicating that MB-treatment did
not affect microglial activity, and in turn microgliosis was not
changed by MB treatment. Our data therefore suggest that the
effect of MB may not be a direct consequence of microglial
inhibition but rather, an affect on neuronal survival. The observed
rescue of motor neurons in pre-clinical stages also supports a
neuroprotective effect of MB.
The observed protective effect seems not only to be primarily
microglia-independent but also independent of the signal molecule
NO, since application of a broad-spectrum NOS inhibitor to
SOD1G93A mice had no effect on the course of disease [50].
Several cellular and molecular mechanisms have been attributed
to the mode of action of MB. Although modulation of the NO
pathway appears to be its main effect, various other cellular and
molecular targets have been described [20,40,47]. Most interest-
ingly, MB can inhibit amyloid Ab oligomerization and thus reduce
Ab oligomer formation, a major hallmark of AD [51]. This led to a
phase II trial using MB for AD patients that showed positive effects
on memory function [21]. In another study, MB inhibited the
aggregation of TAR DNA-binding protein 43 (TDP-43) in vitro
[52,53]. This finding indicates that MB may also have neuropro-
tective effects by reducing aggregate formation or by dissolving
existing aggregates in neurodegenerative diseases. In ALS, tau-
negative and ubiquitine-positive inclusions are observed, with
TDP-43 being a major aggregate component [54,55]. Even
though our study supports the hypothesis of a neuroprotective
effect of MB, immunohistochemistrical investigations showed no
clear alterations of TDP-43-containing aggregates in lumbar
anterior horn neurons by MB treatment. In the recently published
Figure 8. Effect of systemic application of MB on motor neuron survival. (A) NeuN-stained cross-sections of the spinal cord at the level L3 to
L5. Non-treated controls (SOD1G93A mice) are depicted left. Corresponding sections of MB-treated SOD1G93A mice are shown on the right (10 mg oral
per kg body weight per day; drug administration started at the age of 45 days) (B) Counting of neurons in the anterior horn of SOD1G93A mice at
different disease stages. Cell somata bigger than 20 mm were counted and given per mm2. In preclinical stages, neuron number was significantly
higher in MB-treated mice compared to non-treated mice indicating an early neuroprotective effect of MB. Note that no differences were observed in
later disease stages. Values are presented as mean 6 SEM; n = 4 mice for each group; ANOVA followed by Tukey test (*p,0.05).
doi:10.1371/journal.pone.0043963.g008
Figure 9. Effect of systemic application of MB on intracellular
TDP-43-containing aggregates. To analyze intracellular aggrega-
tions in anterior horn neurons, TDP-43 and SMI-32 staining was
performed in lumbar cross-sections. TDP-43-containing aggregates in
SMI-32-positive neurons were observed in the anterior horn of control
and MB-treated pre-clinical and advanced clinical mice. An exemplary
TDP-43-stained neuron from each group, marked by an arrow, is shown
in the last line of images.
doi:10.1371/journal.pone.0043963.g009
Methylene Blue and Neuroinflammation in ALS
PLOS ONE | www.plosone.org 11 August 2012 | Volume 7 | Issue 8 | e43963
study of Audet et al. [47], SOD1 and TDP-43 aggregations were
nearly unchanged in the respective mouse models for ALS after
treatment with MB. Further studies are therefore necessary to
unravel the neuroprotective effect of MB in ALS mice.
Summing up, potentially beneficial effects of locally applied MB
on inflammatory events contributing to disease progression could
not be reproduced in SOD1G93A mice via systemic administration,
whereas systemic MB application delayed disease onset via
neuroprotection. In vivo imaging turns out to be an appropriate
tool to establish if a supposed anti-inflammatory action of a drug
really exists after systemic application. MB is known to penetrate
the blood-brain-barrier [56,57] and seems to exert neuroprotective
effects in an ALS mouse model as in the case of AD. MB may
therefore represent an already well-studied drug for further
investigation in ALS animal models, and potentially safe for
human trials.
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